Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study.

However, in patients with clinical stage B, the beneficial trend did not reach statistical significance (HR = 0.57, P = 0.34), likely due to limited sample size or number of events, although the direction of benefit was consistent with the overall findings ( Supplementary Table 4 ). 4 Discussion To our knowledge, this study is the first to report on the treatment of stage III NSCLC using a domestically developed CIRT system in China, involving a substantial patient cohort.

also in 111,027 other papers